Peripheral Metabolic Effects of Somatostatin

• Register: ClinicalTrials.gov
• Last refreshed on: 19 February 2015
• Main ID: NCT01062529
• Date of registration: 28/01/2010
• Prospective Registration: No
• Primary sponsor: University of Aarhus
• Public title: Peripheral Metabolic Effects of Somatostatin
• Scientific title: Peripheral Metabolic Effects of Intra Arterial Somatostatin Infusion in Healthy Controls
• Date of first enrolment: October 2009
• Target sample size: 8
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT01062529
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science
• Phase: N/A

Countries of recruitment

Denmark

Contacts

• Name: Jens Otto L Jørgensen, Professor

Key inclusion & exclusion criteria

Inclusion Criteria:

- BMI < 27 kg/m2

- Written informed consent

- Healthy

Exclusion Criteria:

- Any disease

- Any use of medications

- Present or previous malignancy

- Alcohol dependency

- Allergy to trial medication



Age minimum: 18 Years
Age maximum: 50 Years
Gender: Male

Health Condition(s) or Problem(s) studied

Acromegaly

Growth Hormone Deficiency

Diabetes

Intervention(s)

Drug: Somatostatin

Primary Outcome(s)

Plasma levels of glucose [Time Frame: 3 months]

Secondary Outcome(s)

GH signalling [Time Frame: one year]

Serum levels of free fatty acids (FFA) [Time Frame: one year]

Secondary ID(s)

M-2008005

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

The Ministry of Science, Technology and Innovation, Denmark